Mangoceuticals, Inc. has reported significant initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month. The program includes doctor visits, consultations, lab work and prescribed medication, offering a comprehensive solution through the company's telehealth platform. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%. This performance reflects what the company described as growing demand for convenient hormone health solutions delivered through its secure telemedicine platform.
The company expects TRT to serve as a primary growth driver as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025. The $99 monthly price point for the comprehensive TRT program represents a significant value proposition in a market where traditional hormone replacement therapy can cost substantially more when factoring in separate fees for doctor visits, lab work, and medications. MangoRx is focused on developing a variety of men's health and wellness products and services via its telemedicine platform.
The company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx's telemedicine platform for a smooth experience where prescription requests are reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx's partner compounding pharmacy directly to the patient's doorstep. The company's growth strategy includes expanding its presence in the global TRT market alongside oral formulations including PRIME by MangoRx powered by Kyzatrex.
This development matters because it represents a significant shift in how hormone replacement therapy is delivered and priced, potentially making treatment more accessible to a broader population. The dramatic sales growth and reduced customer acquisition costs suggest strong market acceptance of the telehealth model for sensitive health treatments. As the global TRT market continues to expand, Mangoceuticals' success with this affordable, comprehensive program could disrupt traditional healthcare delivery models and create new standards for pricing transparency in men's health services. The company's ability to bundle medical services, consultations, lab work, and medication into a single monthly fee addresses common barriers to treatment access while leveraging telemedicine efficiencies.
